Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Angell

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Advances in Experimental Medicine and Biology|April 30, 2009
Discovery and optimization of a TRAIL R2 agonist for cancer therapyYvonne M Angell, Ashok Bhandari, M Nuria De Francisco, et al.
Effective Clinical Practice : ECP|October 28, 1999
What is a good decision?A Ratliff, M Angell, R W Dow, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
Biphenyl amide p38 kinase inhibitors 2: Optimisation and SARRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|January 14, 2000
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanismK Biggadike, R M Angell, C M Burgess, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2007
N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokineticsPaul Bamborough, Richard M Angell, Inder Bhamra, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2008
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modesRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3Richard M Angell, Francis L Atkinson, Murray J Brown, et al.
Journal of Medicinal Chemistry|March 17, 2021
Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus FusionG Stuart Cockerill, Richard M Angell, Alexandre Bedernjak, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Advances in Experimental Medicine and Biology|April 30, 2009
Discovery and optimization of a TRAIL R2 agonist for cancer therapyYvonne M Angell, Ashok Bhandari, M Nuria De Francisco, et al.
Effective Clinical Practice : ECP|October 28, 1999
What is a good decision?A Ratliff, M Angell, R W Dow, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
Biphenyl amide p38 kinase inhibitors 2: Optimisation and SARRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|January 14, 2000
Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanismK Biggadike, R M Angell, C M Burgess, et al.
Bioorganic & Medicinal Chemistry Letters|June 30, 2007
N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokineticsPaul Bamborough, Richard M Angell, Inder Bhamra, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2008
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modesRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2006
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3Richard M Angell, Francis L Atkinson, Murray J Brown, et al.
Journal of Medicinal Chemistry|March 17, 2021
Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus FusionG Stuart Cockerill, Richard M Angell, Alexandre Bedernjak, et al.
Pageof 14